Johns Hopkins scientists develop nose spray DNA vaccine for tuberculosis

Johns Hopkins scientists have developed a new nose spray DNA vaccine against tuberculosis, targeting a persistent challenge in TB treatment: bacteria that hide from antibiotics. In animal studies, the vaccine accelerated infection clearance, reduced lung inflammation, and prevented relapse even after treatment. It also enhanced the effectiveness of existing drugs against drug-resistant TB strains—a growing global health threat. While these results are promising, the vaccine remains in animal testing, so human trials will be needed before it reaches patients.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton